Targovax announces appointment of Erik Digman Wiklund as CFO
Oslo, Norway, 5 January 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that Erik Digman Wiklund has been appointed as the Company's new Chief Financial Officer, and will take up this role in April 2017. The previous CFO, Oystein Soug, was appointed as Targovax's CEO on 2 November 2016. Erik joins from the nutraceutical company Aker Biomarine Antarctic AS, where he held the position as Director of Product Innovation. Prior to joining Aker Biomarine, Erik worked for